Promising FDA Designation Poised to Propel Precision BioSciences
AI Prediction of Precision BioSciences, Inc. Common Stock (DTIL)
Precision BioSciences, a genome editing company, is poised for potentially significant developments with its innovative ARCUS platform and the PBGENE-DMD treatment for Duchenne Muscular Dystrophy. The company recently received FDA Rare Pediatric Disease Designation for PBGENE-DMD, marking a critical step towards clinical trials and possible future FDA approval. These advancements could serve as major catalysts for the company's stock performance in the near future.
Precision BioSciences, operating in the competitive biotech sector, specializes in genome editing with its proprietary ARCUS platform, focusing on delivering gene-based therapies for diseases with significant unmet medical needs. The company's standout program, PBGENE-DMD, aimed at treating Duchenne Muscular Dystrophy, has recently received the FDA's Rare Pediatric Disease Designation. This designation not only underscores the treatment's potential impact, addressing a critical market need but also positions the company to potentially receive a Priority Review Voucher upon approval, which can be financially lucrative. Precision BioSciences is also advancing other programs, including PBGENE-HBV for chronic Hepatitis B, underscoring its strategic focus on high-stakes, high-reward therapeutic areas. Given these developments and the strategic positioning of its pipeline, Precision BioSciences is at a pivotal juncture where upcoming clinical data and regulatory milestones could substantially influence its valuation and investor interest.
DTIL Report Information
Prediction Date2025-07-07
Close @ Prediction$4.34
Mkt Cap101m
IPO Date2019-03-28
AI-derived Information
Recent News for DTIL
- Mar 2 — Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis (Business Wire)
- Feb 26 — Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
- Feb 23 — Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
- Feb 18 — Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference (Business Wire)
- Jan 12 — Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy (Business Wire)
- Dec 23 — Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
- Nov 19 — Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 (Business Wire)
- Nov 19 — Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 (Business Wire)
- Nov 10 — Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants (Business Wire)
- Nov 10 — Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts (Business Wire)
- Nov 3 — Precision BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
- Nov 3 — Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
NDAPR events for DTIL
-
2026-01-12 12:06Revision: NO_CHANGE | Price Pressure Direction: YES_UP | Thesis Unchanged?: YES_UNCHANGEDRationale: Positive clinical advancements and strong financial position support continued bullish outlook.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.